Emanuel F. Iii Petricoin
#121,578
Most Influential Person Now
Emanuel F. Iii Petricoin's AcademicInfluence.com Rankings
Emanuel F. Iii Petricoinbiology Degrees
Biology
#7397
World Rank
#10317
Historical Rank
Neuroscience
#957
World Rank
#997
Historical Rank
Biochemistry
#1019
World Rank
#1132
Historical Rank
Download Badge
Biology
Emanuel F. Iii Petricoin's Degrees
- PhD Biochemistry University of Maryland, College Park
- Masters Biology University of Maryland, College Park
- Bachelors Biology University of Maryland, College Park
Similar Degrees You Can Earn
Why Is Emanuel F. Iii Petricoin Influential?
(Suggest an Edit or Addition)Emanuel F. Iii Petricoin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Use of proteomic patterns in serum to identify ovarian cancer (2002) (3136)
- Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. (2003) (2209)
- Laser-capture microdissection (2006) (1290)
- Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front (2001) (933)
- Serum proteomic patterns for detection of prostate cancer. (2002) (754)
- Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance (2007) (621)
- Early detection: Proteomic applications for the early detection of cancer (2003) (583)
- Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. (1995) (579)
- Clinical proteomics: translating benchside promise into bedside reality (2002) (550)
- Clinical proteomics: Written in blood (2003) (495)
- Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. (1995) (474)
- Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays (2003) (463)
- Protein microarrays: meeting analytical challenges for clinical applications. (2003) (424)
- Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. (2005) (386)
- 2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* (2002) (383)
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (2019) (380)
- Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. (1993) (340)
- Breast cancer growth prevention by statins. (2006) (339)
- The blood peptidome: a higher dimension of information content for cancer biomarker discovery (2006) (334)
- SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. (2004) (327)
- Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study (2007) (316)
- Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma* (2005) (311)
- An investigation into the human serum “interactome” (2004) (299)
- Proteomics of human breast ductal carcinoma in situ. (2002) (289)
- Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. (2005) (253)
- Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines (2000) (241)
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. (2020) (237)
- Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. (2007) (234)
- Medical applications of microarray technologies: a regulatory science perspective (2002) (230)
- Protein microarrays: Molecular profiling technologies for clinical specimens (2003) (225)
- Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. (2000) (220)
- Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays (2003) (220)
- Clinical proteomics: personalized molecular medicine. (2001) (216)
- Biomarker Amplification by Serum Carrier Protein Binding (2004) (201)
- A Portrait of Tissue Phosphoprotein Stability in the Clinical Tissue Procurement Process* (2008) (201)
- An approach to proteomic analysis of human tumors (2000) (197)
- Signal pathway profiling of prostate cancer using reverse phase protein arrays (2003) (194)
- Protein microarray detection strategies: focus on direct detection technologies. (2004) (188)
- Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. (2016) (182)
- Analysis of albumin-associated peptides and proteins from ovarian cancer patients. (2005) (182)
- Phosphorylation Events Modulate the Ability of Interferon Consensus Sequence Binding Protein to Interact with Interferon Regulatory Factors and to Bind DNA* (1997) (181)
- Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. (2005) (180)
- Proteomic analysis of eccrine sweat: implications for the discovery of schizophrenia biomarker proteins. (2012) (178)
- Evaluation of ethanol‐fixed, paraffin‐embedded tissues for proteomic applications (2003) (172)
- Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. (2011) (171)
- Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma (2017) (166)
- Human Proteinpedia enables sharing of human protein data (2008) (164)
- Proteins, drug targets and the mechanisms they control: the simple truth about complex networks (2007) (163)
- Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip (2000) (158)
- Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer (2003) (153)
- Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival (2010) (146)
- Proteomic analysis of human prostate cancer † (2002) (141)
- Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. (2009) (137)
- Serum proteomics in cancer diagnosis and management. (2004) (136)
- Antiproliferative action of interferon-α requires components of T-cell-receptor signalling (1997) (136)
- Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report (2014) (134)
- Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. (2008) (134)
- New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. (2001) (129)
- Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative (2018) (126)
- Asymmetric cancer cell division regulated by AKT (2011) (124)
- Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies (2020) (123)
- Clinical Proteomics: From Biomarker Discovery and Cell Signaling Profiles to Individualized Personal Therapy (2005) (122)
- Technology Insight: pharmacoproteomics for cancer—promises of patient-tailored medicine using protein microarrays (2006) (122)
- Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. (2003) (121)
- Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. (2004) (119)
- Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays. (2005) (119)
- Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway (1997) (116)
- Ovarian cancer detection by logical analysis of proteomic data (2004) (116)
- Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. (2008) (116)
- Clinical potential of proteomics in the diagnosis of ovarian cancer (2002) (116)
- Secreted Neutral Metalloproteases of Bacillus anthracis as Candidate Pathogenic Factors* (2006) (113)
- A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. (2007) (110)
- Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. (2004) (109)
- The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia (2012) (108)
- Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. (2002) (108)
- Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest (2015) (107)
- Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma (2005) (107)
- Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping (2012) (104)
- Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis (2014) (99)
- Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. (2003) (98)
- Analysis of mass spectral serum profiles for biomarker selection (2005) (96)
- Tissue is alive: New technologies are needed to address the problems of protein biomarker pre‐analytical variability (2009) (95)
- Dynamic Profiling of the Post-translational Modifications and Interaction Partners of Epidermal Growth Factor Receptor Signaling after Stimulation by Epidermal Growth Factor Using Extended Range Proteomic Analysis (ERPA)*S (2006) (94)
- Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity (2017) (94)
- Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray (2004) (93)
- Clinical Proteomics and Biomarker Discovery (2004) (93)
- Multifunctional Core–Shell Nanoparticles: Discovery of Previously Invisible Biomarkers (2011) (92)
- A mathematical model of combination therapy using the EGFR signaling network. (2005) (92)
- Importance of communication between producers and consumers of publicly available experimental data. (2005) (91)
- Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers (2009) (90)
- Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer (2007) (87)
- An initial characterization of the serum phosphoproteome. (2009) (87)
- Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection (2004) (86)
- The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells (2016) (86)
- Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. (2019) (86)
- The needle in the haystack: Application of breast fine‐needle aspirate samples to quantitative protein microarray technology (2007) (86)
- Selective binding and enrichment for low‐molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles (2006) (85)
- Clinical applications of proteomics. (2003) (85)
- Clinical Applications of Proteomics: Proteomic Pattern Diagnostics (2002) (84)
- Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer (2008) (83)
- Growth hormone and erythropoietin differentially activate DNA-binding proteins by tyrosine phosphorylation (1994) (83)
- Genomic and proteomic technologies for individualisation and improvement of cancer treatment. (2004) (83)
- The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer (2015) (82)
- The amplified peptidome: the new treasure chest of candidate biomarkers. (2006) (79)
- One-Step Preservation of Phosphoproteins and Tissue Morphology at Room Temperature for Diagnostic and Research Specimens (2011) (79)
- Biomarkers of ovarian tumours. (2004) (77)
- The granulin-epithelin precursor/PC-cell-derived growth factor is a growth factor for epithelial ovarian cancer. (2003) (77)
- Proteomic analysis of lymph (2004) (77)
- Cancer proteomics: from biomarker discovery to signal pathway profiling. (2001) (77)
- Prolactin activates the interferon-regulated p91 transcription factor and the Jak2 kinase by tyrosine phosphorylation. (1994) (76)
- Targetable T-type Calcium Channels Drive Glioblastoma. (2017) (75)
- Functional Protein Pathway Activation Mapping of the Progression of Normal Skin to Squamous Cell Carcinoma (2012) (75)
- The Vision for a New Diagnostic Paradigm (2003) (74)
- The role of proteomics in prostate cancer research: biomarker discovery and validation. (2013) (73)
- Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. (2006) (72)
- Application of molecular technologies for phosphoproteomic analysis of clinical samples (2014) (70)
- Combination of SELDI-TOF-MS and Data Mining Provides Early-stage Response Prediction for Rectal Tumors Undergoing Multimodal Neoadjuvant Therapy (2007) (69)
- Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. (2017) (69)
- Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. (2012) (68)
- Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy (2004) (67)
- Pathology of the Future: Molecular Profiling for Targeted Therapy (2005) (66)
- A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer (2014) (66)
- Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing (2010) (66)
- Molecular Diagnostics (2023) (65)
- Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. (2010) (65)
- Mass spectrometry analysis of the post-translational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells. (2010) (65)
- Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery. (2010) (64)
- Clinical proteomics: Applications for prostate cancer biomarker discovery and detection. (2004) (64)
- BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib (2012) (64)
- Mitochondrial proteome: Cancer‐altered metabolism associated with cytochrome c oxidase subunit level variation (2004) (62)
- Physicochemically modified silicon as a substrate for protein microarrays. (2007) (62)
- Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. (2012) (62)
- DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial (2017) (61)
- Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. (2009) (61)
- Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer (2011) (61)
- Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer (2017) (60)
- Reverse-Phase Phosphoproteome Analysis of Signaling Pathways Induced by Rift Valley Fever Virus in Human Small Airway Epithelial Cells (2010) (59)
- Drosophila screening model for metastasis: Semaphorin 5c is required for l(2)gl cancer phenotype (2003) (59)
- Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. (2019) (58)
- Nanoparticles: potential biomarker harvesters. (2006) (58)
- Proteomic approaches in cancer risk and response assessment. (2004) (58)
- The Use of Nanotrap Particles Technology in Capturing HIV-1 Virions and Viral Proteins from Infected Cells (2014) (58)
- IL-4 attenuates the transcriptional activation of both IFN-alpha and IFN-gamma-induced cellular gene expression in monocytes and monocytic cell lines. (1993) (57)
- Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles (2008) (56)
- Using Decision Forest to Classify Prostate Cancer Samples on the Basis of SELDI-TOF MS Data: Assessing Chance Correlation and Prediction Confidence (2004) (54)
- Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations (2017) (54)
- Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis (2015) (53)
- Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology (2010) (53)
- Reverse Phase Protein Microarrays. (2017) (52)
- Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling. (1997) (51)
- Quantum dots for biomedical applications. (2008) (50)
- Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. (2011) (50)
- A systems biology approach to the pathogenesis of obesity‐related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis (2007) (50)
- Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. (2007) (49)
- Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. (2009) (49)
- Inhibition of alpha interferon but not gamma interferon signal transduction by phorbol esters is mediated by a tyrosine phosphatase (1996) (48)
- Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers (2020) (47)
- A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients (2019) (47)
- Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL (2010) (47)
- Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology (2009) (46)
- Reverse-phase protein microarrays for theranostics and patient tailored therapy. (2009) (45)
- The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease. (2011) (44)
- Proteomic analysis at the bedside: early detection of cancer. (2002) (44)
- Activation of Raf-1 by Interferon γ and Oncostatin M Requires Expression of the Stat1 Transcription Factor* (1998) (44)
- A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. (2005) (43)
- Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis (2015) (43)
- HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer (2013) (43)
- Proteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer's hippocampus from normal controls (2016) (43)
- Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. (1998) (42)
- Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with “-OMIC” Data Fields and Therapeutic Response Signatures (2013) (41)
- Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. (2014) (41)
- Truncated ErbB2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB2 Kinase Inhibitors (2011) (41)
- Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. (2005) (40)
- Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. (2009) (39)
- Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations. (2011) (39)
- Human cancer cell lines express a negative transcriptional regulator of the interferon regulatory factor family of DNA binding proteins. (1994) (39)
- Development of multiplexed protein profiling and detection using near infrared detection of reverse-phase protein microarrays (2004) (39)
- Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer (2017) (39)
- Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. (2019) (38)
- Preparation and Use of Reverse Protein Microarrays (2014) (38)
- Serum S100A6 Concentration Predicts Peritoneal Tumor Burden in Mice with Epithelial Ovarian Cancer and Is Associated with Advanced Stage in Patients (2009) (38)
- Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. (2011) (38)
- Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion (2015) (38)
- Lysophosphatidic Acid Down-Regulates Stress Fibers and Up-Regulates Pro–Matrix Metalloproteinase-2 Activation in Ovarian Cancer Cells (2007) (38)
- A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. (2017) (37)
- The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma (2017) (36)
- The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells (2019) (36)
- Opportunities for Nanotechnology-Based Innovation in Tissue Proteomics (2004) (36)
- Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis. (2016) (36)
- Laser Capture Microdissection: Beyond Functional Genomics to Proteomics (2000) (36)
- The Role of IKKβ in Venezuelan Equine Encephalitis Virus Infection (2014) (35)
- Reverse phase protein microarrays for monitoring biological responses. (2007) (35)
- Reverse-phase protein microarrays for tissue-based analysis. (2005) (34)
- Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. (2008) (34)
- Fractionation of serum components using nanoporous substrates. (2006) (34)
- Lessons from Kitty Hawk: From feasibility to routine clinical use for the field of proteomic pattern diagnostics (2004) (34)
- Counterpoint: The vision for a new diagnostic paradigm. (2003) (33)
- Discovery of Mouse Spleen Signaling Responses to Anthrax using Label-Free Quantitative Phosphoproteomics via Mass Spectrometry* (2010) (33)
- Use of proteomic patterns to screen for gastrointestinal malignancies. (2004) (33)
- Elevated TNFR1 and Serotonin in Bone Metastasis Are Correlated with Poor Survival following Bone Metastasis Diagnosis for Both Carcinoma and Sarcoma Primary Tumors (2013) (33)
- Cytokines that associate with the signal transducer gp130 activate the interferon-induced transcription factor p91 by tyrosine phosphorylation. (1994) (32)
- Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition (2013) (32)
- The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. (2007) (32)
- Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. (2014) (32)
- Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. (2005) (32)
- Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693 (2010) (31)
- Individualized therapy for metastatic colorectal cancer (2013) (31)
- Activation of the PI3K/Akt/mTOR and MAPK Signaling Pathways in Response to Acute Solar-Simulated Light Exposure of Human Skin (2015) (31)
- Resatorvid‐based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV‐induced NF‐κB and AP‐1 Signaling in Keratinocytes and Mouse Skin (2016) (31)
- Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. (2009) (30)
- Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). (2009) (30)
- Improved reproducibility of reverse‐phase protein microarrays using array microenvironment normalization (2009) (30)
- Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine (2015) (30)
- The spectra count label-free quantitation in cancer proteomics. (2012) (29)
- Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. (2007) (29)
- General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. (2003) (29)
- Mass spectrometry-based protein biomarker discovery: solving the remaining challenges to reach the promise of clinical benefit. (2010) (28)
- Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma (2018) (28)
- Cancer metabolism and mass spectrometry-based proteomics. (2015) (28)
- Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example (2017) (27)
- Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors (2015) (27)
- Analysis of the lsi region involved in lipooligosaccharide biosynthesis in Neisseria gonorrhoeae (1991) (27)
- The use of Nanotrap particles for biodefense and emerging infectious disease diagnostics (2014) (27)
- Fingerprinting of signal transduction pathways using a combination of anti‐phosphotyrosine immunoprecipitations and two‐dimensional polyacrylamide gel electrophoresis (2001) (27)
- Use of transformation to construct Neisseria gonorrhoeae strains with altered lipooligosaccharides (1988) (27)
- Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. (2005) (27)
- Clinical Proteomics for Cancer Biomarker Discovery and Therapeutic Targeting (2002) (27)
- Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. (2010) (27)
- Modulation of interferon signaling in human fibroblasts by phorbol esters (1992) (26)
- Preclinical magnetic resonance imaging and systems biology in cancer research: current applications and challenges. (2013) (26)
- A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping (2012) (26)
- Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice (2018) (26)
- Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH. (2009) (26)
- Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. (2014) (26)
- Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines (2012) (26)
- Cancer biomarkers: closer to delivering on their promise. (2011) (26)
- Divergence of binding, signaling, and biological responses to recombinant human hybrid IFN. (1999) (26)
- Profiling of normal human leg lymph proteins using the 2-D electrophoresis and SELDI-TOF mass spectrophotometry approach. (2004) (26)
- Reverse phase protein microarrays for theranostics and patient-tailored therapy. (2008) (25)
- Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. (2015) (25)
- Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). (2009) (25)
- A Novel Function of RNAs Arising From the Long Terminal Repeat of Human Endogenous Retrovirus 9 in Cell Cycle Arrest (2012) (24)
- Development of a novel proteomic approach for mitochondrial proteomics from cardiac tissue from patients with atrial fibrillation. (2011) (24)
- Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL. (2018) (24)
- Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells (2009) (24)
- Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. (2017) (23)
- Reverse phase protein microarrays for clinical applications. (2011) (23)
- Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy (2015) (23)
- FINDbase: a worldwide database for genetic variation allele frequencies updated (2010) (23)
- Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers (2019) (23)
- Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy (2010) (23)
- Molecular Profiling of Pancreatic Cancer Patients—Response (2018) (22)
- Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways (2012) (22)
- Molecular analysis of lipooligosaccharide biosynthesis in Neisseria gonorrhoeae (1989) (22)
- Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia (2015) (22)
- Network-targeted combination therapy : a new concept in cancer treatment (2004) (22)
- Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. (2022) (22)
- Molecular and clinical characterization of BRAF mutations in pancreatic ductal adenocarcinomas (PDACs). (2018) (21)
- A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative (2016) (21)
- Inhibition of host extracellular signal-regulated kinase (ERK) activation decreases new world alphavirus multiplication in infected cells (2014) (21)
- Modeling of protein signaling networks in clinical proteomics. (2005) (21)
- Nanotechnology in clinical proteomics. (2007) (21)
- Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial (2021) (21)
- Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. (2008) (21)
- Multifactorial Analysis of Conditional Reprogramming of Human Keratinocytes (2015) (20)
- Mass Spectrometry-Based Biomarker Discovery. (2017) (20)
- Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas (2015) (20)
- -Omics and Cancer Biomarkers: Link to the Biological Truth or Bear the Consequences (2012) (20)
- Cancer metabolism: what we can learn from proteomic analysis by mass spectrometry. (2012) (20)
- Reverse phase protein microarrays: fluorometric and colorimetric detection. (2011) (20)
- APPLICATION OF LASER CAPTURE MICRODISSECTION AND PROTEIN MICROARRAY TECHNOLOGIES IN THE MOLECULAR ANALYSIS OF AIRWAY INJURY FOLLOWING POLLUTION PARTICLE EXPOSURE (2004) (19)
- A method for the selective isolation and enrichment of carrier protein‐bound low‐molecular weight proteins and peptides in the blood (2007) (19)
- Novel Approaches to Visualization and Data Mining Reveals Diagnostic Information in the Low Amplitude Region of Serum Mass Spectra from Ovarian Cancer Patients (2004) (18)
- Clinical proteomics: application at the bedside. (2004) (18)
- Proteomics Discovery of Disease Biomarkers (2008) (18)
- Transcriptomic and phospho‐proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera (2013) (18)
- Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer (2021) (18)
- Interferon-alpha-induced gene expression: evidence for a selective effect of ouabain on activation of the ISGF3 transcription complex. (1992) (18)
- Beyond the genome to tissue proteomics (1999) (18)
- Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program. (2019) (17)
- Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells. (2019) (17)
- Integration of Network Biology and Imaging to Study Cancer Phenotypes and Responses (2014) (16)
- Protein Microarray Analysis of Mammary Epithelial Cells from Obese and Nonobese Women at High Risk for Breast Cancer: Feasibility Data (2011) (16)
- Blasting into the Microworld of Tissue Proteomics: A New Window on Cancer (2004) (16)
- Virtual reality and augmented reality: Advances in surgery (2017) (16)
- Proteomic patterns in serum and identification of ovarian cancer (2002) (16)
- Synthesis and characterization of hydrogel particles containing Cibacron Blue F3G-A. (2010) (16)
- Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations (2013) (16)
- Protein quantification by mass spectrometry: is it ready for prime time? (2009) (15)
- Discovery of Infectious Disease Biomarkers in Murine Anthrax Model Using Mass Spectrometry of the Low-Molecular-Mass Serum Proteome (2009) (15)
- The Obama Administration's Cancer Moonshot: A Call for Proteomics (2016) (15)
- Augmented Reality Imaging System: 3D Viewing of a Breast Cancer. (2016) (15)
- Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer (2018) (15)
- New Approaches to Molecular Profiling of Tissue Samples (2000) (15)
- Profiling the activity of G proteins in patient‐derived tissues by rapid affinity‐capture of signal transduction proteins (GRASP) (2004) (15)
- Regulatory approval pathways for molecular diagnostic technology. (2012) (14)
- Application of physicochemically modified silicon substrates as reverse-phase protein microarrays. (2009) (14)
- Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. (2017) (14)
- Reverse-phase protein microarrays. (2012) (14)
- Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial (2020) (13)
- Dilution of protein gel stain results in retention of staining capacity. (2003) (13)
- Cofilin hyperactivation in HIV infection and targeting the cofilin pathway using an anti-α4β7 integrin antibody (2019) (13)
- The Warburg Effect and Mass Spectrometry-based Proteomic Analysis. (2017) (13)
- Reverse phase protein microarrays and their utility in drug development. (2013) (13)
- Analysis of urinary human growth hormone (hGH) using hydrogel nanoparticles and isoform differential immunoassays after short recombinant hGH treatment: preliminary results. (2013) (13)
- Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example (2013) (13)
- Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance (Proceedings of the National Academy of Sciences of the United States of America (2007) 104, 41 (16158-16163)) (2007) (13)
- A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray (2016) (13)
- Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin (2016) (13)
- Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). (2011) (12)
- A New Scientific Journal Linked to a Genetic Database: Towards a Novel Publication Modality (2008) (12)
- Augmented Reality and Virtual Reality: Initial Successes in Diagnostic Radiology (2018) (12)
- Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells (2017) (12)
- Proteomic strategies for the discovery of novel diagnostic and therapeutic targets for infectious diseases (2014) (12)
- Multi-omic molecular comparison of primary versus metastatic pancreatic tumours (2019) (11)
- Role of Bruton’s tyrosine kinase inhibitors in HIV-1-infected cells (2015) (11)
- Clinical Application of Proteomics in Ovarian Cancer Prevention and Treatment (2012) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Mathematical modeling of the cancer cell’s control circuitry : paving the way to individualized therapeutic strategies (2007) (11)
- MS analysis reveals O‐methylation of L‐lactate dehydrogenase from pancreatic ductal adenocarcinoma cells (2012) (11)
- CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment (2021) (11)
- Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors. (2021) (10)
- Host response during Yersinia pestis infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways (2015) (10)
- Particle swarm optimization for analysis of mass spectral serum profiles (2005) (10)
- Application of Analyte Harvesting Nanoparticle Technology to the Measurement of Urinary HGH in Healthy Individuals. (2012) (10)
- Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma (2015) (10)
- Dynamic Regulation of Caveolin-1 Phosphorylation and Caveolae Formation by mTORC2 in Bladder Cancer Cells. (2019) (10)
- The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer (2021) (10)
- D3D augmented reality imaging system: proof of concept in mammography (2016) (10)
- Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection (2018) (10)
- Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine (2016) (10)
- Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. (2019) (10)
- Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers (2017) (9)
- A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer. (2013) (9)
- Proteomic Technologies to Study Diseases of the Lymphatic Vascular System (2002) (9)
- High Resolution Mapping of the Cardiac Transmural Proteome Using Reverse Phase Protein Microarrays* (2011) (9)
- Molecular profiling of cancer and drug-induced toxicity using new proteomic technologies (2001) (9)
- Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens (2021) (9)
- Seropositivity of COVID-19 among asymptomatic healthcare workers: A multi-site prospective cohort study from Northern Virginia, United States (2021) (9)
- Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation (2020) (9)
- Use of xylE fusions to demonstrate that lsi-1, a Neisseria gonorrhoeae lipooligosaccharide biosynthetic gene, and lsi-3 are not transcriptionally linked (1994) (9)
- Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection (2020) (9)
- Stratification of clear cell renal cell carcinoma by signaling pathway analysis (2014) (9)
- RPPA: Origins, Transition to a Validated Clinical Research Tool, and Next Generations of the Technology. (2019) (9)
- Data standards for proteomics: mitochondrial two-dimensional polyacrylamide gel electrophoresis data as a model system. (2004) (9)
- Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. (2009) (9)
- Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer (2021) (8)
- Erratum: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse (Cancer Cell (4) (437-450)) (2004) (8)
- A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. (2016) (8)
- An exploratory study examining how nano-liquid chromatography–mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease (2018) (8)
- Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature. (2021) (8)
- Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology (2015) (8)
- Abstract 5492: Inhibition of ERK MAPK signaling increases pancreatic cancer dependency on autophagy (2018) (8)
- Erratum: Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria (Cell Chemical Biology (2017) 24(10) (1259–1275.e6) (S2451945617302830)(10.1016/j.chembiol.2017.08.009)) (2017) (8)
- IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK (2021) (7)
- Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis. (2019) (7)
- The NF-κB/leukemia inhibitory factor/STAT3 signaling pathway in antibody-mediated suppression of Sindbis virus replication in neurons (2020) (7)
- Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities (2020) (7)
- Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies. (2020) (7)
- Convergent evolution of p38/MAPK activation in hormone resistant prostate cancer mediates pro-survival, immune evasive, and metastatic phenotypes (2020) (7)
- Protein network construction using reverse phase protein array data. (2017) (7)
- Serum 99 th Percentile Reference Cutoffs for Seven Cardiac Troponin Assays (2004) (7)
- Mass spectrometry‐based characterization of the vitreous phosphoproteome (2010) (7)
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer (2021) (7)
- Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015 (2018) (7)
- Combining markers with and without the limit of detection (2014) (7)
- Innovations in Clinical Trial Design in the Era of Molecular Profiling. (2017) (7)
- Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. (2012) (7)
- PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells (2020) (7)
- Lipoarabinomannan antigenic epitope differences in tuberculosis disease subtypes (2020) (6)
- Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL (2017) (6)
- Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. (2003) (6)
- Trapping radioactive carbon dioxide during cellular metabolic assays under standard culture conditions: description of a unique gas-capturing device. (2004) (6)
- Critical dependence of blood-borne biomarker concentrations on the half-lives of their carrier proteins. (2008) (6)
- Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light (2017) (6)
- Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors (2019) (6)
- Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies (2021) (6)
- Mass Spectrometry-Based Protein Biomarker Discovery and Measurement: Sensitivity is the Greatest Hurdle (2010) (6)
- Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. (2017) (6)
- The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria (2021) (6)
- Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs (2022) (5)
- Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-199) (2015) (5)
- Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer. (2022) (5)
- Therapeutic Discovery Truncated ErbB 2 Expressed in Tumor Cell Nuclei Contributes to Acquired Therapeutic Resistance to ErbB 2 Kinase Inhibitors (2011) (5)
- Regulation of Chemosensitivity in Human Medulloblastoma Cells by p53 and the PI3 Kinase Signaling Pathway (2021) (5)
- The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow (2020) (5)
- Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial (2020) (5)
- Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations (2019) (5)
- Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial. (2019) (5)
- Exosomes originating from infection with the cytoplasmic single-stranded RNA virus Rift Valley fever virus (RVFV) protect recipient cells by inducing RIG-I mediated IFN-B response that leads to activation of autophagy (2021) (5)
- Development of Nanoparticle-Enabled Protein Biomarker Discovery: Implementation for Saliva-Based Traumatic Brain Injury Detection (2015) (5)
- Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells (2013) (5)
- Evaluation of pathogen specific urinary peptides in tick-borne illnesses (2020) (5)
- Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (2020) (5)
- Antitumor effect of insulin‐like growth factor‐1 receptor inhibition in head and neck squamous cell carcinoma (2020) (5)
- Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. (2009) (5)
- Activation of Protein Kinase A Inhibits Interferon Induction of the Jak / Stat Pathway in U 266 Cells * (1996) (5)
- Development of a novel hybrid alphavirus-SARS-CoV-2 particle for rapid in vitro screening and quantification of neutralization antibodies, viral variants, and antiviral drugs (2020) (4)
- Protein Pathway Activation Mapping for Multi-Omic Based Precision Medicine (2016) (4)
- RESPONSE: Re: Serum Proteomic Patterns for Detection of Prostate Cancer (2003) (4)
- Proteomics of breast cancer (2006) (4)
- Clinical application of proteomics in ovarian cancer prevention and treatment. (2009) (4)
- Functional and biological heterogeneity of KRASQ61 mutations (2022) (4)
- Erratum to: ‘Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology’ (2015) (4)
- Molecular Technologies for Personalized Cancer Management (2004) (4)
- A Revolutionary approach to biomarker discovery (2006) (4)
- Application of sector protein microarrays to clinical samples (2004) (4)
- A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers. (2018) (4)
- Bovine apolipoprotein B100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans (2007) (4)
- Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial (2019) (4)
- PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine (2021) (4)
- A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution’s experience (2020) (3)
- A phase I dose-escalation study of 5-day intermittent oral lapatinib therapy with biomarker analysis in patients with HER-2-overexpressing breast cancer. (2009) (3)
- Multi-omic profiling of metastatic lesions to guide treatment selection: The Side Out 2 trial experience. (2018) (3)
- Phosphoproteomic Analysis of Pancreatic Ductal Adenocarcinoma Cells Reveals Differential Phosphorylation of Cell Adhesion, Cell Junction and Structural Proteins (2011) (3)
- Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. (2022) (3)
- Multi-Omic profiling (MoP) for patients (pts) with pancreatic cancer (PDA): Initial results of the Know Your Tumor (KYT) initiative. (2016) (3)
- Abstract P3-07-48: Prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: Exploratory protein pathway marker results from the I-SPY 2 trial (2016) (3)
- Genomic and Proteomic Pathway Mapping Reveals Signatures of Mesenchymal-Epithelial Plasticity in Inflammatory Breast Cancer (2011) (3)
- Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial (2021) (3)
- A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies (2019) (3)
- The Know Your Tumor (KYT) initiative: A national program of multi-omic molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA). (2016) (3)
- Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study. (2017) (3)
- Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping. (2009) (3)
- Esophageal Squamous Cell Cancer-Specific Protein Markers (2001) (3)
- Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response (2021) (3)
- Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active (2019) (3)
- IgA autoreactivity towards brain enriched and apoptosis regulating proteins in saliva of athletes after acute concussion and subconcussive impacts. (2021) (3)
- Microspheres Containing Cibacron Blue F3G-A and Incorporated Iron Oxide Nanoparticles as Biomarker Harvesting Platforms (2011) (3)
- HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL. (2019) (3)
- Increased PD‐L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation (2021) (3)
- BM-15TARGETING MEK IS A NOVEL AND EFFECTIVE TREATMENT STRATEGY OF LUNG CNS METASTASIS (2014) (3)
- Mass spectrometry-based biomarker discovery. (2012) (2)
- Induction of nerve growth factor by phorbol 12-myristate 13-acetate is dependent upon the mitogen activated protein kinase pathway (2018) (2)
- Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days (2021) (2)
- Transcriptosome and Phospho-Proteomic Analyses of Erythroblasts Expanded in Vitro From Normal Donors (ND) and From Patients with Polycythemia Vera (PV). (2012) (2)
- Signal transduction pathways in non-small cell lung cancer: Characterization of adenocarcinoma and squamous cell carcinoma histologic subtypes (2004) (2)
- Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner (2022) (2)
- Phosphorylation of AKT kinase substrates to predict response to the AKT inhibitor MK2206 in the I-SPY 2 trial in both HER2- and HER2+ patients. (2018) (2)
- Abstract 4787: Novel upfront sample enrichment nanotechnology identifies prostate, breast, colon, ovarian, lung, pancreatic, and melanoma cancer specific biomarker candidates (2012) (2)
- Use of protein pathway mapping of brain metastasis from breast and lung cancer patients to identify new therapeutic targets: A seed/soil study. (2010) (2)
- Protein pathway activation mapping guided biomarker development to identify optimal combinations of MEK inhibitor with PI3K/mTOR pathway inhibitors for the treatment of triple-negative breast cancer. (2013) (2)
- Development of a quantitative PD-L1 assay using laser capture microdissection (LCM)-based reverse phase protein microarray (RPPA) workflow: Implications for precision medicine. (2018) (2)
- Use of protein pathway activation mapping of NSCLC to identify distinct molecular subtypes and a prognostic signature for aggressive node-negative tumors. (2010) (2)
- Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial (2021) (2)
- Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future (2018) (2)
- Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray (2006) (2)
- PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis (2020) (2)
- Importance of disclosure of patent applications (2004) (2)
- Molecular Diagnostics (2003) (2)
- Proteomic profiling identifies prognostic subsets in Rhabdomyosarcoma (RMS) (2005) (2)
- Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program. (2018) (2)
- Abstract 5656: Quantitative measurement of PDL1 expression across tumor types using laser capture microdissection and reverse phase protein microarray (2017) (2)
- Regorafenib in metastatic colorectal cancer: An exploratory biomarker trial. (2016) (2)
- Abstract 1755: TORK/DNA-PK inhibitor CC-115 is effective as a single agent in a subset of glioblastoma patient-derived cancer stem cells and xenografts and potentiates temozolomide therapy (2015) (2)
- Protein activation mapping and exploratory predictive markers for pCR in triple-negative breast cancer patients treated with neratinib in the I-SPY 2 TRIAL. (2015) (2)
- Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways (2022) (1)
- Clinical proteomics and molecular pathology (2020) (1)
- Multiplex proteomic analysis of cells in fine needle aspiration samples: how soon can we expect to individualize therapy by comparing pre- and posttreatment biopsies? (2014) (1)
- A reevaluation of annexin I expression in normal breast and breast carcinoma (2005) (1)
- The promise of proteomics. (2003) (1)
- Aurora Kinases in Childhood Acute Leukemia: The Promise of Aurora Kinase B As Drugable Target (2011) (1)
- Abstract B49: Alpha-enolase knockdown reprograms metabolism and points out targetable pathways to counteract PDA growth (2015) (1)
- Prolonged STAT 1 Activation Related to the Growth Arrest of Malignant Lymphoma Cells by Interferon-a By (1998) (1)
- Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models (2021) (1)
- Predictive value of topoisomerase 1 by immunohistochemistry (TOP1 IHC) in patients with metastatic breast cancer receiving irinotecan-based therapy. (2016) (1)
- Abstract 3129: PD-L1 expression differs across cancer metastatic sites from breast tumors (2018) (1)
- CABOZANTINIB IS EFFECTIVE IN A SUBSET OF XENOGRAFT GBM TUMORS AND AFFECTS MULTIPLE SIGNALING PATHWAYS (2014) (1)
- Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis (2017) (1)
- Protein molecular profiling of archival and frozen fine needle aspirate material in human breast cancer before and after therapy (2005) (1)
- Chapter 9 – Clinical Proteomics and Molecular Pathology (2009) (1)
- Abstract 1889: Can the moonlighting glycolytic enzyme α-enolase be a therapeutic target in pancreatic cancer. (2013) (1)
- Preliminary observations of blood-based (BB) molecular testing in a subset of patients with pancreatic cancer (PDA) participating in the Know Your Tumor (KYT) initiative. (2016) (1)
- Abstract P1-21-08: Application of machine learning to elucidate the biology predicting response in the I-SPY 2 neoadjuvant breast cancer trial (2020) (1)
- Phase I/II personalized therapy trial for metastatic colorectal cancer using functional pathway mapping: Stratification to imatinib therapy. (2010) (1)
- Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study (2017) (1)
- Charge Transport Phenomena in Peptide Molecular Junctions (2008) (1)
- Proteomics in laboratory medicine. Preface. (2009) (1)
- Abstract 5575: Mass spectrometry analysis of the posttranslational modifications of alpha-enolase from pancreatic ductal adenocarcinoma cells (2010) (1)
- Development and Clinical Implementation of Reverse Phase Protein Microarrays for Protein Network Activation Mapping: Personalized Cancer Therapy (2012) (1)
- Viral Neutralization is Durable in Asymptomatic COVID-19 for at least 60 Days. (2021) (1)
- CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. (2020) (1)
- Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial (2020) (1)
- Integrated multi-omic analyses reveals clinical relevance of endometrial cancer cell line models (2021) (1)
- Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas (2021) (1)
- Abstract P3-04-02: Protein pathway activation mapping of I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with HR+/HER2− tumors (2012) (1)
- Androgen receptor (AR) activation in breast cancer (BC) liver metastases. (2017) (1)
- Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3) (2019) (1)
- Molecular biomarkers as predictors of patient survival in pancreatic adenocarcinoma (PDA): An analysis of the Know Your Tumor initiative (KYT). (2017) (1)
- Abstract 2244: Pharmacological TLR4 antagonism using topical resatorvid blocks solar UV-induced skin tumorigenesis in SKH-1 mice (2017) (1)
- Protein pathway analysis in Clinical Proteomics using protein microarrays. (2005) (1)
- Basic techniques for the use of reverse phase protein microarrays for signal pathway profiling (2005) (1)
- Precision Oncology for Pancreatic Cancer across the United States: the Know Your Tumor ® experience (2019) (1)
- Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture mass spectrometry. (2010) (1)
- Abstract P2-04-02: Identifying molecular targets and mechanisms of treatment resistance in inflammatory breast cancer (IBC) using reverse-phase protein microarrays (RPMA) (2015) (1)
- Development and pilot evaluation of a new nanoparticle-capture workflow for doxorubicin-induced toxicity biomarker identification (2015) (1)
- 295 Proteomic and Circulating Free DNA Analysis Outcome Predictors in the GALAXY TrialTM (NCT01348126): a Randomized Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIb/IV NSCLC (2012) (1)
- Use of functional protein pathway activation mapping in glioblastoma samples to differentiate long-term from short-term survivors along with pathway-driven molecular subgroups. (2010) (1)
- Abstract 822: Predicting response to kinase inhibitors based on tumor genomics in NF1-related MPNSTs (2018) (0)
- Cancer Metastasis: Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy (2011) (0)
- Abstract P1-07-23: Pathway activation mapping of metastatic breast cancer identifies potential organ-specific signatures: Implications for patient stratification to targeted treatment (2015) (0)
- Abstract LB-216: Protein pathway activation analysis of a panel of patient-derived epithelial tumor models identifies signatures of response to ErbB1-3 co-targeting (2018) (0)
- Abstract 3246: Mapping of functional protein pathway modulations in non-sun exposed skin of healthy volunteers using solar simulated light: A new model for pharmacodynamic testing of skin cancer chemopreventive drugs (2014) (0)
- Synthesis of 2-oxoquinoline derivatives as dual pim and mTORC protein kinase inhibitors (2022) (0)
- Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx). (2019) (0)
- Salivary proteomic profile of patients with renal cell carcinoma. (2020) (0)
- Sa1089 Proteomic Analysis of ITPA SNP rs1127354 Chronic Hepatitis C (Ch-C) Patients Indicates Differential Regulation of Apoptosis Pathway Components (2012) (0)
- Alterations of Cell Signaling Pathways in Pediatric B-ALL Patients. (2006) (0)
- Abstract C16: Feasibility study: Protein profiling of primary breast cancers from premenopausal women (2014) (0)
- Abstract 2917: Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma (2011) (0)
- REDUCED ANNEXIN A1 EXPRESSION CONTRIBUTES TO PROSTATE CANCER BY ACTIVATION OF AKT AND INDUCTION OF IL-6 (2008) (0)
- Title: the Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer Statement of Translational Relevance (2015) (0)
- Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treatKRAS-mutant pancreatic cancer (2019) (0)
- Cellular Reprogramming of Epithelial Cells Leading to Conditional Immortalization is Accompanied by Changes in Multiple Pathways (2015) (0)
- Protein network mapping of platinum-resistant and poor-survival ovarian cancer. (2013) (0)
- Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer (2022) (0)
- Phosphoproteomic Analysis of Intracellular Signaling in the Human Hepatic Tissue of Patients with Non-Alcoholic Fatty Liver Disease and Fibrosis (2016) (0)
- 382 PROTEIN PATHWAY BIOMARKER SIGNATURE ASSOCIATED WITH SUPERIMPOSED NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C (2010) (0)
- Practical Management of Liver Diseases: Novel Technologies in Studying Chronic Liver Disease (2008) (0)
- Abstract 4893: AKT1 signaling negatively regulates invasion and metastasis of non-small cell lung cancer cells carrying mutations in KRAS or EGFR (2017) (0)
- Reverse Phase Protein Microarray Technology (2013) (0)
- Phosphoproteomic analysis of metastatic colorectal cancer: A new horizon in targeted therapy development (2006) (0)
- Real-world outcomes in pancreatic adenocarcinoma (PDAC) and persona types with implications for standard of care (SOC) therapy (Tx). (2020) (0)
- Abstract 102: Overcoming MET inhibitor resistance in GBM therapy (2017) (0)
- Abstract P4-07-51: Impact of the Theralink CLIA protein/phosphoprotein assay on treatment selection in routine clinical practice: a prospective observational study in advanced breast cancer (2023) (0)
- 1081: Signal Pathway Profiles Based on Histologic Grade of Human Prostate Cancer Using Reverse Phase Protein Microarrays (2004) (0)
- Abstract PR10: Enhancing the effect of autophagy inhibition for pancreatic cancer treatment (2019) (0)
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer (2021) (0)
- 129 – Repurposing the Fda Approved Drug Pyrvinium Pamoate to Target Hur in Pancreatic Ductal Adenocarcinoma (2019) (0)
- Abstract B034: Determination of KRAS- and ERK-regulated phosphoproteomes in KRAS-mutant cancers (2023) (0)
- Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial. (2018) (0)
- Signal-pathway profiling of cells undergoing photodynamic therapy with reverse phase liquid protein arrays. (2004) (0)
- Abstract 3290: The Side-Out Foundation Metastatic Breast Cancer Database, an open-access portal for multi-omic molecular data and more (2018) (0)
- Abstract 1994: Impact of laser capture microdissection on cancer signaling proteins and phosphoproteins (2015) (0)
- Proteomic analysis of lymph (Proteomics 2004, vol. 4, issue 3, pp. 753–765) (2004) (0)
- Abstract 5248: The use of reverse phase protein array (RPPA) to identify new tumor vulnerability and actionable drug targets against human cancer cell lines (2023) (0)
- Protein network mapping of glucose metabolism in ovarian cancer. (2014) (0)
- p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs (2023) (0)
- GENO-12CLONAL EVOLUTION AND GENOMIC DIVERSITY IN A PANEL GLIOBLASTOMA TUMORS, NEUROSPHERE CULTURES AND ORTHOTOPIC XENOGRAFTS. (2015) (0)
- Abstract P4-10-31: Patterns of protein expression and signaling assessed by reverse phase protein array (RPPA) in estrogen-receptor negative (ER-), HER2-amplified breast cancer (BC) that was primary-refractory to preoperative (preop) HER2-directed therapy (2020) (0)
- 764 A novel strategy for topical photochemoprevention: Pharmacological TLR4 antagonism blocks non-melanoma skin cancer (2017) (0)
- Multiomic molecular comparison of primary versus metastatic pancreatic tumors. (2018) (0)
- A phosphoproteomic comparison of L858R-mutant with wild-type EGFR signaling in NSCLC cell lines (2007) (0)
- Activation of non-canonical cKIT signalling in erythroid progenitor cells from polycythemia vera (2017) (0)
- Comprar Proteomics in Laboratory Medicine, An Issue of Clinics in Laboratory Medicine | Emanuel F. Petricoin | 9781437704938 | Saunders (2009) (0)
- Abstract 4141: Tumor cell enrichment is critical for assessing cell signaling pathways in glioblastoma multiforme. (2013) (0)
- The potentiative cytotoxic effect of IGF1R and EGFR inhibition on the Head and Neck Cancer Proteome (2022) (0)
- Regulation of the addition of 0-side chains on lipooligosaccharide in Neisseria gonorrhoeae (1991) (0)
- Combination therapy optimization in gastrointestinal cancers using multi-omic molecular profiling. (2018) (0)
- Abstract P3-06-15: Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 trial (2015) (0)
- Magnetization of hydrogel particles: a novel urine tuberculosis antigen test (2013) (0)
- Abstract PS12-14: Phase II trial of fulvestrant plus enzalutamide in ER+/Her2- advanced breast cancer (2021) (0)
- The Molecular Crosstalk Between Hepatic Tissue and Visceral Adipose Tissue in Patients with Obesity-Related Nonalcoholic Fatty Liver Disease (NAFLD): The Interactions between Inflammation and Immune Activation (2017) (0)
- Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection (2020) (0)
- 575 Immunohistochemical evaluation of proteins within UV signal transduction pathways in the progression of normal human skin to matched sun-damaged skin and actinic keratosis (2016) (0)
- Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer (2021) (0)
- Abstract 4384: Quantitative assessment of drug combination effects in NSCLC cell lines through network-based analysis of functional protein activity (2020) (0)
- Phosphoprotein pathway mapping: AKT/mTOR activation is negatively associated with childhood Rhabdomyosarcoma survival (2006) (0)
- Validation of ATAD2 and cMYC Copy Number and Gene Expression in Breast Brain Metastasis (BBM, n = 42) and Early-Stage Primary Breast Cancer Samples (n = 50). (2014) (0)
- Abstract 4091: Functional genomic screening in gemcitabine and cisplatin resistant bladder cancer cell lines identifies DNA repair pathways as mediators of chemosensitivity (2020) (0)
- Functional pathway mapping of human glioblastoma multiforme and brain metastases for patient tailored therapy. (2009) (0)
- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures (2016) (0)
- Nano LC- mass spectrometry based proteomic profiling associated with significant fibrosis and collagen deposition in non-alcoholic fatty liver disease (NAFLD) (2017) (0)
- Use of Protein Microarrays for Molecular Network Analysis and Signal-Pathway Profiling (2007) (0)
- Different Stress Responses Mediate the Massive Erythroblast Expansion Occurring in Cultures of Human Progenitor Cells Derived From Cord Blood and Adult Blood in the Presence of Glucocorticoid Receptor Agonists. (2012) (0)
- Abstract 1854: Treatment of head and neck squamous cell carcinoma cells with BMS754807 and Dasatinib induce synergistic cytotoxicity through altered focal adhesion signaling (2018) (0)
- Hydrogel particles sequester and preserve low molecular weight, low abundance cancer biomarkers in blood (2008) (0)
- Abstract #1793: Comparison of gene expression and reverse-phase protein microarray profiling for prediction of chemosensitivity to lapatinib in human bladder cancer (2009) (0)
- Corrections (2006) (0)
- Development and Implementation of Array Technologies for Proteomics: Clinical Implications and Applications (2011) (0)
- Abstract CN07-03: IL6 and AKT as targets for chemoprevention (2011) (0)
- Abstract 3147: Comprehensive characterization of the role of T-type calcium channels in glioblastoma (2017) (0)
- Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations (2017) (0)
- Abstract 5553: A computational model for integrating genomic data with public datasets for molecular tumor board recommendations (2017) (0)
- Functional characterization of human cancer stem cells for targeted therapy (2008) (0)
- populations cultured in FCS in mice and humans Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell (2013) (0)
- Gene Expression and Proteomic Analysis to Identify Predictive Biomarkers of Response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept Study Evaluating First-Line Ganetespib Monotherapy in Women with Metastatic HER2 Positive or Triple Negative Breast Cancer (TNBC) (2014) (0)
- Abstract 991: Development and characterization of patient derived xenografts from central nervous system metastasis reveal minor clone expansion linked with aggressive tumor behavior (2018) (0)
- MA04.06 Signaling Networks in KRAS-Mutant Advanced NSCLC: A Complex Landscape Involving Immunoresponse, Inflammation and DNA Repair (2017) (0)
- Alterations in molecular networks of metastatic colorectal carcinoma reveal organ-specific signatures: Implications for targeted therapy of metastatic disease. (2006) (0)
- Pathway Analysis of Serum Analytes and Phosphorylated Proteins and their Involvement in Regulatory Pathways in Patients with Non-Alcoholic Steatohepatitis (NASH) (2017) (0)
- Inflammatory Mediators as Therapeutic Targets for Inflammatory Breast Cancer (2012) (0)
- The need for a human proteome project--all aboard? Insights from a conference organized by the Cambridge Healthtech Institute. (2001) (0)
- ATPS-01INHIBITION OF T-TYPE CALCIUM CHANNELS SENSITIZES GLIOBLASTOMA STEM CELLS TO CHEMOTHERAPY (2015) (0)
- 1087 PROTEIN PATHWAY BIOMARKERS PREDICTING SUSTAINED VIROLOGIC RESPONSE (SVR) TO PEGYLATED INTERFERON (PEG-IFN) AND RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC HEPATITIS C (CH-C) (2010) (0)
- Abstract HER2-17: HER2-17 Novel Quantitative HER2 Assay for Determining Dynamic HER2 Expression in the HER2 IHC 0 “Ultra-Low” Setting: Implications for Precision Therapy in HER2- Breast Cancer (2023) (0)
- Abstract 2254: Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools (2018) (0)
- Qualification of Microarrayers for Clinical Research : Results From Testing of the BioOdyssey (2007) (0)
- Molecular network analysis of signaling pathways in metastatic breast cancer in patients treated with erlotinib. (2006) (0)
- The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia (2012) (0)
- Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer. (2022) (0)
- LungMATCH: Rates of molecular testing in the lung cancer community. (2017) (0)
- Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents (2023) (0)
- Visualizing real-world outcomes through the lens of a molecular tumor board: Persona-typing pancreatic cancers for clinical decision support. (2019) (0)
- 3 Overview of proteomics with emphasis on diagnosis and monitoring (2004) (0)
- Author Correction: Lipoarabinomannan antigenic epitope differences in tuberculosis disease subtypes (2021) (0)
- Association of Serum and Liver Proteomic Profiling of Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) Reveals Common Pathways Linking Non-Alcoholic Steatohepatitis (NASH) and Metabolic Abnormalities (2017) (0)
- Faculty Opinions recommendation of Regional differences in multinational clinical trials: anticipating chance variation. (2010) (0)
- Abstract 222: Protein network mapping of bladder cancer: tumor compartment and microenvironment analysis (2017) (0)
- Abstract 2239: Bone metastasis protein signaling pathway mapping in seven primary tumor types via Reverse Phase Protein Microarray (2010) (0)
- Methode d'isolement d'analytes provenant d'un echantillon (2006) (0)
- Abstract B54: miR-125b and miR-17-3p: Newly identified tumor suppressors for prostate cancer (2012) (0)
- STUDENTJAMA. Molecular technologies for personalized cancer management. (2004) (0)
- Abstract 5893: Comprehensive proteogenomic analysis and classification of lung adenocarcinoma (2020) (0)
- Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach (2022) (0)
- Protein network mapping of retinoblastomas for the identification of therapeutic targets. (2014) (0)
- Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors (2022) (0)
- Abstract B12: Overcoming acquired resistance to vemurafenib using clinically relevant PDX models of melanoma. (2013) (0)
- P1-06-11: Comparison of Community and Central Her2 Assessment on Outcome of Neoadjuvant Chemotherapy in the I-SPY Trial. (2011) (0)
- Abstract A2: Autoantibody signature in pancreatic ductal adenocarcinoma. (2012) (0)
- Proteomic Analysis of Surrogate Tissues: Mass Spectrometry-Based Profiling of the Circulatory Proteome for Cancer Detection and Stratification (2005) (0)
- Abstract 2000: Different oncogenic KRAS mutations produce distinct heterogenous outcomes in signaling pathways of isogenic mouse embryonic fibroblasts (2021) (0)
- Abstract A108: Phosphoprotein network activation during breast cancer initiation (2010) (0)
- Abstract 2912: Protein pathway activation mapping of leukemia-associated JAK1 mutants (2011) (0)
- Abstract P2-05-21: The AKT-mTOR pathway as a potential organ-specific drug target signature of hepatic metastases from breast cancer (2016) (0)
- Abstract 4585: Verification of prostate cancer biomarker candidates by nanoparticle-capture MRM (2010) (0)
- Hepatic microRNA and phosphoproteomic analysis provide insights about hepatic collagen deposition and stage of fibrosis in non-alcoholic steatohepatitis (2018) (0)
- 795 Protein Pathway Activation Mapping of KRAS Mutated NSCLC Clinical Samples Reveals Systemic Pathway Alterations and Point to New Therapeutic Targets for EGFR Resistant Tumors (2012) (0)
- Rapid Detection of Biological and Chemical Threat Agents Using Physical Chemistry, Active Detection, and Computational Analysis (2007) (0)
- Abstract 1213: Comparing protein pathway activation mapping portraits between gliobastoma patient-matched primary tumor, xenografts and neurospheres: implications for precision medicine (2014) (0)
- Faculty Opinions recommendation of Motivating the unmotivated for health behavior change: a randomized trial of cessation induction for smokers. (2010) (0)
- Abstract P3-05-02: Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization (2017) (0)
- Abstract 2925: Protein pathway activation mapping of the NCI60 cell line series: Discovery of lineage-independent protein biomarkers for drug sensitivity/resistance prediction (2011) (0)
- Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (2016) (0)
- DCIS neoadjuvant therapy: Targeting the autophagy pathway in malignant precursor cells. (2010) (0)
- 389 - Endogenous Gastrin Collaborates with Mutant Kras in Pancreatic Carcinogenesis (2018) (0)
- P2.15-13 Implementation of a Democratized Approach to Multi-Omic Molecular Profiling Via the LungMATCH Program. (2018) (0)
- Abstract 5180: The neuroreticular axis modulates cell signaling kinases in bone metastasis (2011) (0)
- AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers (2023) (0)
- Exosomes originating from infection with the cytoplasmic single-stranded RNA virus Rift Valley fever virus (RVFV) protect recipient cells by inducing RIG-I mediated IFN-B response that leads to activation of autophagy (2021) (0)
- Abstract 4847: Identifying molecular targets and mechanisms of treatment resistance in inflammatory breast cancer (IBC) using next-generation sequencing (NGS) and reverse-phase protein microarrays (RPMA) (2015) (0)
- Protein microarray analysis of aberrant signaling pathways in Acute Myeloid Leukemia to predict the patients responsiveness to PI3K/Akt/mTOR inhibitors (2011) (0)
- Development and Use of Reversed‐Phase Protein Microarrays for Clinical Applications (2008) (0)
- 358 Proteomic pattern analysis serum for early detection of ovarian cancer (2003) (0)
- Abstract 2043: Protein pathway activation mapping analysis of metastatic breast cancer reveals potential new targets for personalized therapy. (2013) (0)
- Semi-quantitative protein analysis of HER2 and ER levels in human breast cancer reveals broad expression ranges within HER2+ and ER+ phenotypes. (2009) (0)
- Abstract 3795: Cabozantinib affects multiple signaling pathways in glioblastoma and is effective in a subset of xenograft tumors (2014) (0)
- Proteomic and Circulating Free DNA Analysis Outcome Predictors in the Galaxy Trialtm (NCT01348126): A Randomized Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIB/IV NSCLC (2012) (0)
- Abstract 1829: PRAS40 as a mediator of insulin-like growth factor-1 receptor-induced resistance to epidermal growth factor receptor inhibition in head and neck cancer (2018) (0)
- Role of DNA methylatìon in the growth of Neisseria gonorrhoeae (1991) (0)
- Toward a systems biology software toolkit (2004) (0)
- Abstract 44: Hexyl-benzyl-biguanide (HBB) potently and selectively inhibits CYP3A4 epoxygenase activity and inhibits EET stabilization of mitochondrial respiration in ER+HER2- breast cancer cells, inducing glycolysis and pyruvate biosynthesis (2016) (0)
- Abstract P3-06-37: I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial (2015) (0)
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (2019) (0)
- Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis (2015) (0)
- Abstract 1080: Nanotechnology-enhanced proteomics analysis of a unique prospective collection of blood samples for the discovery and validation of early detection biomarkers for Non-Small Cell Lung Cancer (NSCLC). (2013) (0)
- Protein signal pathway mapping of human breast cancer from I-SPY: Correlations with response and genomic subtyping. (2010) (0)
- Erratum: Pilot and feasibility study: Prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways (Breast Cancer Research and Treatment (2012) 132 (487-498) DOI: 10.1007/s10549-011-1609-9) (2012) (0)
- Abstract A65: Effects of alpha-enolase silencing in adenocarcinoma pancreatic cell line. (2012) (0)
- The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow (2020) (0)
- Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma (2018) (0)
- Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers (2022) (0)
- Abstract PS12-06: Phase II randomized trial of fulvestrant with or without enzalutamide in ER+/Her2- primary breast cancer (BC) (2021) (0)
- Abstract 4575: Covalent incorporation of a new class of dye-based affinity baits in sieving hydrogel nanoparticles overcome roadblocks to cancer biomarker discovery (2010) (0)
- Abstract P6-04-01: Protein pathway activation mapping of LCM tumor epithelium from I-SPY 1 TRIAL surgical specimens reveals activation of receptor tyrosine kinase drug target signaling networks in the non-responding patient cohort (2013) (0)
- Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis (2022) (0)
- Abstract PD5-02: PD5-02 An Organoid Model System to Study Resistance Mechanisms, Predictive Biomarkers, and New Strategies to Overcome Therapeutic Resistance in Early-Stage Triple-Negative Breast Cancer (2023) (0)
- 771 Increased PD-L1 expression in human skin acutely and chronically exposed to UV irradiation (2019) (0)
- Author response for "Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial" (2021) (0)
- Erratum to: Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways (2012) (0)
- Abstract B11: Multi-omic interrogation of gemcitabine and cisplatin-resistant bladder cancer cell lines identifies unique and shared mediators of chemosensitivity and resistance (2020) (0)
- Abstract 3158:In vivoacquired resistance to an emibetuzumab analogue inMET-amplified gastric xenografts can be overcome by a MET-targeting antibody mixture or PIK3CA/AKT/mTOR inhibition (2017) (0)
- Ex Vivo Multiplexed Signal Pathway Inhibitor Treatment Reveals Differential Sensitivity of Myeloma and Non-Myeloma Bone Marrow Cell Populations. (2009) (0)
- Abstract 5451: Longitudinal proteomic assessment of patient with metastatic apocrine adenocarcinoma reveals evolutionary selection for androgen-receptor-dependence and therapeutic response (2020) (0)
- Pattern Recognition Algorithms and Disease Biomarkers (2005) (0)
- Androgen receptor activation in HER2-negative breast cancer liver metastases. (2016) (0)
- Abstract 1612: Gene expression and proteomic analysis to identify predictive biomarkers of response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2 positive or triple negat (2014) (0)
- Pinpointing a marker protein in papillary bladder carcinomas using SELDI mass spectrometry and microdissection (2004) (0)
- Abstract P1-07-09: A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer (2017) (0)
- Genetic Alterations in Prostatic Intraepithelial Neoplasia (PIN) (2001) (0)
- Proteomic Profiling of Hepatic Metastases: Paving the Way to Individualized Therapy (2011) (0)
- Multiplatform profiling of pancreatic neuroendocrine tumors (PanNETs) identifies novel co-occurring pathogenic alterations and associations with clinicopathologic factors. (2019) (0)
- Abstract 4911: Systems level network analysis of NCI60 cell lines by alignment of protein pathway activation modules with multiple -omic data fields and therapeutic response signatures (2012) (0)
- 93: A Panel of Potential Diagnostic Biomarkers for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (2007) (0)
- Abstract P3-04-01: Protein pathway activation mapping of the I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with triple negative tumors: (2012) (0)
- Differential Modulation Of cKIT Signaling By CD63 Dictates The Magnitude Of Response To Stem Cell Factor Of Erythroblasts From Adult Blood, Cord Blood and Polycythemia Vera (2013) (0)
- CCL-2 and Soluble Fas Ligand as Markers of Hepatic Fibrosis in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): 331 (2011) (0)
- P1.01-036 Identifying and Addressing Gaps in Molecular Testing for Patients with Lung Cancer (2017) (0)
- Abstract 2867: Laboratory analyses of metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide (2021) (0)
- comparative cellular signal patway analysis of metastatic colorectal cancer in human and preclinical animal model (2008) (0)
- Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients (2016) (0)
- Abstract LB102: Hexyl-(cuban-1-yl-methyl)-biguanide (HCB) suppresses N-glycosylation of immune checkpoint proteins B7-H3 and B7-H4, reverses tumor hypoxia, decreases intratumoral regulatory T cells, and increases intratumoral CD8+ T cells in the ovarian dependent ER+HER2- SSM2ucd mammary cancer allo (2023) (0)
- Abstract 93: Molecular profiling of pancreatic cancer patients from a wide geographical distribution across the US (2016) (0)
- Abstract 3312: Protein activation pathway analysis of glioblastoma stem cells reveals potential novel biomarkers (2011) (0)
- Abstract PD5-08: PD5-08 Drug target activation mapping of matched triple negative primary and axillary lymph node metastases identifies and links the ER-AR-GR steroid hormone receptor axis with downstream AKT activation (2023) (0)
- Clinical proteomics (2007) (0)
- Mo1298 THE CHALLENGE OF LOCAL PANCREATIC BIOPSY FOR MOLECULAR PROFILING IN PANCREATIC CANCER: REAL WORLD EXPERIENCE RESULTS USING A MULTI-OMIC BASED PRECISION MEDICINE PLATFORM IMPLEMENTED FOR THE KNOW YOUR TUMOR® PROGRAM (2018) (0)
- The Proteomic Approach to Prostate Cancer (2013) (0)
- Abstract B26: Addressing gaps in molecular testing for patients with lung cancer (2018) (0)
- Protein signal pathway mapping: Screening potential drug targets for Multiple Myeloma (2008) (0)
- Abstract 1993: Off-target effects of ultra-low dose dimethyl sulfoxide on targetable signaling events in lung cancer in vitro models (2021) (0)
- Abstract 358: Identification of signaling pathways activated by BCAR4 expression in human breast cancer (2011) (0)
- Use of a prognostic pathway signature for colorectal cancer comprised of EGFR/COX2 and imatinib drug target activation to predict occult metastasis in M0 CRC. (2009) (0)
- Exploring the proteome as a response predictor for rectal cancer undergoing neoadjuvant radiochemotherapy (RCT) (2005) (0)
- Reply: (2007) (0)
- Personalized therapy for metastatic colorectal cancer: A closer possibility? (2007) (0)
- Abstract P5-03-12: DNA repair genes are more frequently mutated in non-white populations of metastatic breast cancer (MBC) patients (2023) (0)
- Abstract 2145: Detect early tumor relapse in high-risk breast cancer (2019) (0)
- Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer (2021) (0)
- Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (2020) (0)
- Identification and validation of aberrantly expressed proteins in breast ductal carcinoma in situ (DCIS) and esophageal squamous cell carcinoma (ESCC) (2002) (0)
- Cancer proteomics in the discovery of new biomarkers for diagnosis and treatment (2008) (0)
- Outcome driven persona-typing for precision oncology: Beyond a genomics centered view of individualized therapy. (2018) (0)
- Phosphoproteomic Analysis Identifies Dynamic Regulation of Caveolin‐1 Phosphorylation and Caveolae Formation by mTORC2 in Bladder Cancer Cells (2018) (0)
- Phase I study: Safety and tolerability of varlitinib (VAR) in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours. (2018) (0)
- Correlation of VEGFR activation within the tumor-associated stroma with an aggressive colon cancer phenotype (2012) (0)
- 312 Protein Pathway Biomarkers Predicting Sustained Virologic Response (SVR) to Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) in Treatment-Naive Genotype 1 Patients With Chronic Hepatitis C (Ch-C) (2010) (0)
- Correction: Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection (2018) (0)
- Abstract 3465: Impact of intratumoral protein signaling network activation heterogeneity: Implication for precision medicine (2014) (0)
- Abstract B1-14: A machine learning approach applied to Reverse Phase Protein Microarray data for pathways activation mapping of KRAS wild type and mutated adenocarcinomas of the lung (2015) (0)
- LOW‐MOLECULAR WEIGHT PROTEINS IN NORMAL SUBJECTS AND PATIENTS WIYH INFLAMMATORY LYMPH STASIS: 431 (2004) (0)
- Network-based analysis of reverse phase protein array data (2016) (0)
- Reevaluation of annexin I expression in benign breast tissue and breast cancer (2006) (0)
- Abstract P3-10-02: Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: Lessons from ˜1000 patients across 10 arms of the I-SPY 2 TRIAL (2019) (0)
- Phosphoproteomic analysis of matched primary breast cancer (BC) and lymph node (LN) metastases. (2017) (0)
- Use of an ex vivo multiplexed signal pathway inhibitor treatment to reveal sensitivity of myeloma and nonmyeloma bone marrow cell populations. (2010) (0)
- Abstract B038: Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer (2018) (0)
- Abstract C27: Association of mutant KRAS isoforms with weight loss in pancreatic cancer (2019) (0)
- Importance of disclosure of patent applications. Authors' reply (2004) (0)
- Abstract P4-08-13: The Use of Reverse Phase Protein Arrays (RPPA), Principal Component Analysis (PCA), and CScape Pathway Mapping to Identify New Tumor Vulnerability and Actionable Targets in Human Malignant Triple-Negative Breast cancer cell lines (2023) (0)
- Implementation of a democratized approach to multi-omic molecular profiling via the LungMATCH program. (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Emanuel F. Iii Petricoin?
Emanuel F. Iii Petricoin is affiliated with the following schools:
